Cargando…
Risankizumab in the treatment of psoriasis – literature review
Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis. The aim of the work is to collect up-to-date information on risankizumab and present its mechanism o...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710847/ https://www.ncbi.nlm.nih.gov/pubmed/31462831 http://dx.doi.org/10.5114/reum.2019.86426 |
_version_ | 1783446421722103808 |
---|---|
author | Banaszczyk, Katarzyna |
author_facet | Banaszczyk, Katarzyna |
author_sort | Banaszczyk, Katarzyna |
collection | PubMed |
description | Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis. The aim of the work is to collect up-to-date information on risankizumab and present its mechanism of action and recent clinical trials in which it was applied. This work also compares the mechanisms of action of risankizumab and ustekinumab and their importance in the treatment of psoriasis and describes the role of IL-23 in the etiopathogenesis of psoriasis. The work also refers to the effectiveness of risankizumab treatment and its safety profile. The results of molecular and histological studies that show changes in psoriatic skin after risankizumab treatment are also described. |
format | Online Article Text |
id | pubmed-6710847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie |
record_format | MEDLINE/PubMed |
spelling | pubmed-67108472019-08-28 Risankizumab in the treatment of psoriasis – literature review Banaszczyk, Katarzyna Reumatologia Review Paper Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis. The aim of the work is to collect up-to-date information on risankizumab and present its mechanism of action and recent clinical trials in which it was applied. This work also compares the mechanisms of action of risankizumab and ustekinumab and their importance in the treatment of psoriasis and describes the role of IL-23 in the etiopathogenesis of psoriasis. The work also refers to the effectiveness of risankizumab treatment and its safety profile. The results of molecular and histological studies that show changes in psoriatic skin after risankizumab treatment are also described. Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2019-06-28 2019 /pmc/articles/PMC6710847/ /pubmed/31462831 http://dx.doi.org/10.5114/reum.2019.86426 Text en Copyright: © 2019 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Review Paper Banaszczyk, Katarzyna Risankizumab in the treatment of psoriasis – literature review |
title | Risankizumab in the treatment of psoriasis – literature review |
title_full | Risankizumab in the treatment of psoriasis – literature review |
title_fullStr | Risankizumab in the treatment of psoriasis – literature review |
title_full_unstemmed | Risankizumab in the treatment of psoriasis – literature review |
title_short | Risankizumab in the treatment of psoriasis – literature review |
title_sort | risankizumab in the treatment of psoriasis – literature review |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710847/ https://www.ncbi.nlm.nih.gov/pubmed/31462831 http://dx.doi.org/10.5114/reum.2019.86426 |
work_keys_str_mv | AT banaszczykkatarzyna risankizumabinthetreatmentofpsoriasisliteraturereview |